Sarepta Begins Enrollment for Enhanced Elevidys Regimen in Non-Ambulant Duchenne Patients
summarizeSummary
Sarepta Therapeutics has announced that screening and enrollment are underway for Endeavor Cohort 8, which will evaluate an enhanced immunosuppression regimen for its Elevidys gene therapy. This specific cohort targets non-ambulant individuals with Duchenne muscular dystrophy. This development is significant as it demonstrates Sarepta's continued efforts to optimize and expand the utility of Elevidys, especially following previous regulatory setbacks for the therapy that contributed to a significant net loss in 2025. The initiation of this new cohort suggests a proactive approach to address patient needs and potentially improve treatment outcomes, which could be a positive catalyst for the stock as the company works to overcome past challenges.
At the time of this announcement, SRPT was trading at $16.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $10.42 to $103.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.